agn 1

AGN 192836 is a potent and selective α2 adrenergic agonist with EC50s of 8.7 nM, 41 nM, and 6.6 nM for the α2A, α2B, and α2C receptors, respectively.

AGN 194078 is a selective RARα agonist with a dissociation constant (Kd) of 3 nM and an effective concentration (EC50) of 112 nM.

AGN 196996 is a potent and selective inhibitor of RARα (Ki: 2 nM), exhibiting very low affinity for RARβ (Ki: 1087 nM) and RARγ (Ki: 8523 nM).

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd= 2, 2, and 3 nM for RARα, β, and γ, respectively), exhibiting selectivity for RARs over retinoid X receptors (RXRs; Kd= >10,000 nM for human RXRα, β, and γ receptors). This compound effectively reverses cellular morphology changes and growth suppression induced by RAR agonists such as all-trans-RA, 13-cis-RA, and 9-cis-RA in ECE16-1 human endometrial ectocervical epithelial cells, particularly when used at a 10-fold molar excess. Furthermore, AGN 193109 downregulates the expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, indicating inhibition of retinoid action, specifically when co-administered with TTNPB but not as a standalone treatment. In vivo studies demonstrate teratogenic effects, including cleft palate, frontonasal dysplasia, and eye malformations in mouse fetuses following a single oral dose of 1 mg kg.

AGN 194310 (VTP-194310) is a pan-antagonist for retinoic acid receptors (RARs), with Kd values of 3 nM, 2 nM, and 5 nM for RARα, RARβ, and RARγ, respectively[1][2].

AGN 192870 is a potent retinoic acid receptor (RAR) antagonist.AGN 192870 can be used to study cell growth arrest, differentiation and apoptosis.

AGN 192171 is a biochemical.

AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).

AGN 191864 is a biochemical.

AGN 191701 is an agonist of the Retinoid X receptor.

Agn 190727 is a retonoic acid receptor that can induce retinoid-induced hypertriglyceridemia.

AGN 192240 is a biochemical.

AGN 191976 is a novel thromboxane A2-mimetic.

Tazarotenic acid (AGN-190299) is a retinoid prodrug which is converted to its active form

WT-1 A1 is an attractive target for immunotherapy in patients with pancreatic adenocarcinoma.

AGN-190383 is a phospholipase inhibitor with topical anti-inflammatory activity.

Abicipar pegol (AGN-150998, MP0112), an anti-VEGF DARPin molecule, is a novel class of small ankyrin repeat domain-containing proteins designed for high specificity and affinity targeting. This compound effectively inhibits angiogenesis and vascular permeability, and has been applied in ocular inflammation-related disease studies through intravitreal injections, significantly reducing mean retinal thickness and leakage area [1] [2].

AGN-191129, also known as Prostaglandin F2α alcohol methyl ether (PGF2α-OMe), is an analog of PGF2α in which the C-1 carboxyl group has been replaced by an O-methyl ether. The compound is reported to retain ocular hypotensive properties, but the receptors